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Background: High serum uric acid (UA) is associated with cardiovascular disease, but the mechanism is uncertain. One possible pathway is 
production of a proinflammatory state contributing to the development of insulin resistance and hepatic steatosis. We assessed the association 
of high UA with high-sensitivity C-reactive protein (hs-CRP); triglyceride to high-density lipoprotein cholesterol (TG/HDL) ratio, a marker of insulin 
resistance; and hepatic steatosis.
Methods: Individuals free of cardiovascular disease were evaluated with an employer-sponsored health screening between December 2004 and 
December 2010. Hepatic steatosis was detected by ultrasound, and the metabolic syndrome was defined by International Diabetes Federation 
criteria. The odds ratios (OR) and confidence intervals (CI) for hs-CRP ≥ 3 mg/L, TG/HDL ratio ≥ 3, and hepatic steatosis in the highest versus lowest 
UA quartiles were determined using multivariate logistic regression.
Results: Among 4,196 individuals (mean age 48 ± 8 years, 82% males), the lowest and highest UA quartiles were 1.6-4.9 and 6.8-11.1 mg/
dl, respectively. The prevalence of hs-CRP ≥ 3 mg/L was 19%, TG/HDL ≥ 3 was 43%, and hepatic steatosis was 42%. Compared to the lowest UA 
quartile, the highest UA quartile had increased OR for hs-CRP ≥ 3 mg/L, TG/HDL ≥ 3, and hepatic steatosis (Table).
Conclusion: Hyperuricemia is associated with systemic inflammation, dyslipidemia of insulin resistance, and hepatic steatosis independent of 
obesity and metabolic syndrome. 
Highest vs. Lowest UA Quartile
OR (95% CI) for
hs-CRP ≥ 3 mg/L
OR (95% CI) for TG/HDL ≥ 3 OR (95% CI) for Hepatic Steatosis
Obesity
Non-obese 1.63* (1.03-2.56) 3.71* (2.74-5.01) 4.14* (3.00-5.74)
Obese 1.80 (0.97-3.34) 3.80* (2.32-6.22) 3.41* (2.08-5.59)
Metabolic syndrome
No metabolic syndrome 1.90* (1.24-2.91) 2.93* (2.16-3.96) 4.16* (3.03-5.71)
Metabolic syndrome 3.50* (1.37-8.94) 2.87* (1.48-5.56) 2.85* (1.63-4.98)
Hepatic steatosis
No hepatic steatosis 1.77* (1.05-2.97) 2.94* (2.05-4.21)
Hepatic steatosis 1.78*(1.004-3.15) 3.20* (2.13-4.81)
*P value < 0.05.
Adjusted for age, gender, hypertension, fasting glucose, presence of diabetes mellitus, diabetes medications, low-density lipoprotein cholesterol, 
lipid medications, smoking status (current smoker or nonsmoker), and physical activity (assessed by the International Physical Activity Questionnaire 
as low, moderate, or high physical activity).
